EN DE

Microbio Co (4128) Fair Value & Analysis

Consumer Defensive · TW · Market cap 9.1B TWD

MC Microbio Co 4128 · TWO
Price14.50 TWD
Fair Value24.57 TWD
Upside+69.5%
Quality48/100
Watch Microbio Co for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -35.7% net margin
generates free cash flow
Trails peers (3/9)
Narrow moat 13/100
Evidence: Medium Range 10.99 TWD – 42.35 TWD Share as image

Fair value as of: Jul 21, 2026

From 8 valuation models · updated 20 days ago

Fair value updated Jul 21, 2026, revised from 24.39 TWD to 24.57 TWD (+0.7%) since Jul 9, 2026. Share price −15.5% over the past month.

Below-average quality, screening 69% undervalued on our models.

What matters now

  • The model range is unusually wide (10.99 TWD to 42.35 TWD). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid quality (48/100) at a price below fair value, the discount is the argument here, not the business quality.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

68.73 TWD 13.85 TWD Fair Value 24.57 TWD Feb 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 21, 2026.

How to read this chart

60‑month range 13.85 TWD – 68.73 TWD · fair‑value band 10.99 TWD – 42.35 TWD · the 14.50 TWD price screens below the 24.57 TWD fair value. Dashed = 300-day average. As of Jul 21, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Microbio Co (4128) currently trades at 14.50 TWD, while our model-based Fair Value estimate is 24.57 TWD, implying the stock looks roughly 69.5% undervalued today. The Quality Score stands at 48/100 (below-average quality), in the Consumer Defensive sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.

Over the trailing twelve months, Microbio Co generated revenue of 1.9B TWD at a net margin of -35.7%. Revenue grew 9.9% year over year. It earns a return on equity of -8.8%. The balance sheet holds a net cash position of 14.5M TWD. Fundamentals as of Jul 21, 2026

Our scenario range runs from 10.99 TWD (bear case) to 42.35 TWD (bull case); at 14.50 TWD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 48% below its 52-week high and 2% above its 52-week low, currently below its 200-day average. For context, the median of 10 Consumer Defensive peers we cover trades at -3% fair-value upside, at 69%, 4128 screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (0.5100 TWD to 10.15 TWD). Read the values as a conservative anchor, not as a price target.
Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 1.51 TWD 1.66 TWD 1.86 TWD 72
Gordon GGM 0.3100 TWD 0.6100 TWD 0.9200 TWD 70
DDM Multi-Stage 0.3100 TWD 0.5100 TWD 0.6400 TWD 61
All 8 models by family
DCF Models
FCF DCF 1.51 TWD 1.67 TWD 1.92 TWD 38
5Y Revenue Exit 1.47 TWD 1.62 TWD 1.81 TWD 39
10Y Revenue Exit 1.47 TWD 1.61 TWD 1.80 TWD 36
Dividend Discount
Gordon GGM 0.3100 TWD 0.6100 TWD 0.9200 TWD 70
DDM Multi-Stage 0.3100 TWD 0.5100 TWD 0.6400 TWD 61
Multiples
EV/Revenue 1.46 TWD 1.56 TWD 1.67 TWD 43
Asset-Based
NCAV (Graham) 7.58 TWD 10.15 TWD 15.15 TWD 50
Growth DCF
Growth DCF 1.51 TWD 1.66 TWD 1.86 TWD 72

Widest divergence: Asset-Based (10.15 TWD) versus Dividend Discount (0.5100 TWD). Highest evidence: Growth DCF (72).

Notify me when 4128 reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 1.9B TWD
Revenue growth (YoY) +9.9%
Net margin -35.7%
Return on equity -8.8%
Free cash flow 16.1M TWD FY2025
Operating margin -22.8%
More key figures
EPS (TTM) -1.29 TWD
EPS growth (YoY) +2,069%
Net cash 14.5M TWD FY2023

Figures from reported company fundamentals · as of Jul 21, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 48/100

Of which business quality 47 · Market factors (momentum, volatility) 29

Profitability 2
Margins and returns on capital today
Quality Growth 48
Are margins and returns improving?
Cashflow 16
Earnings quality: real cash, not paper profit
Fin. Strength 77
Balance sheet, leverage, solvency risk
Investment 97
Disciplined investing over empire-building
Low Volatility 75
Calm price path (market factor)
Momentum 14
Price trend over the last 3–12 months (market factor)
52W Momentum 1
Distance to the 52-week high (market factor)
Net Issuance 73
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea.

Full company description

Microbio Co., Ltd. researches, develops, manufactures, and trades in biotech drugs and dietary supplements in Taiwan. The company provides MS-20 for fatigue and appetite loss associated with cancer chemotherapy; and Herbiron, which reveals symptoms of iron deficiency anemia in women before menopause and relieved dysmenorrhea. It also involved in the trading of organic foods; sale of beverages; provision of technology development, transfer, and consultation services; and publishing of magazine, as well as offers business consulting services. Microbio Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Microbio Co reported revenue of 1.9B TWD in FY2025 versus 1.8B TWD in FY2021, a compound +1.5%/yr. Reported net income was −758M TWD in FY2025.

Growth Quality 37/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
1.9B TWD
Latest YoY
+9.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.2%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+3.4%
Avg. growth/yr (19Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+11.7%
Revenue +1.5%/yr
FY21 1.8B TWD
FY22 1.7B TWD
FY23 1.6B TWD
FY24 1.7B TWD
FY25 1.9B TWD
Net income
FY21 −233M TWD
FY22 152M TWD
FY23 −1.2B TWD
FY24 −1.1B TWD
FY25 −758M TWD

Watch 4128: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Microbio Co Fair Value". https://www.fairvalue-calculator.com/stock/4128

Peer Group

Packaged Foods · 649 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 48 · Below median
Fair Value upside +69% · Top 25%
Return on assets -2% · Bottom 25%
Net margin (TTM) -36% · Bottom 25%
Operating margin (TTM) -23% · Bottom 25%
Revenue growth 10% · Above median

Valuation Multiples vs Packaged Foods median · lower = cheaper

P/S (TTM) 0.15× · Cheaper than 75% of peers
P/FCF 17.6× · Pricier than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 100 · sector 28
FUTURE 50 · sector 20
PAST 0 · sector 27
HEALTH 0 · sector 96
DIVIDEND 0 · sector 47

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Packaged Foods stocks, each showing price versus our Fair Value estimate (as of Jul 21, 2026).

Stock Price Fair Value vs Fair Value
Nestlé India Limited NESTLEIND ₹1,427 ₹362.37 -75%
Britannia Industries Limited BRITANNIA ₹5,413 ₹1,870 -65%
Tata Consumer Products Limited TATACONSUM ₹1,089 ₹327.27 -70%
PT Indofood CBP Sukses Makmur Tbk ICBP 6,650 IDR 15,757 IDR +137%
Samyang Foods Co 003230 1,139,000 KRW 1,010,543 KRW -11%
Patanjali Foods Limited PATANJALI ₹413.80 ₹157.04 -62%
Vietnam Dairy Products Joint Stock Company VNM 58,500 VND 68,259 VND +17%
PT Mayora Indah Tbk, MYOR 1,750 IDR 2,699 IDR +54%
PT Cisarua Mountain Dairy Tbk CMRY 4,490 IDR 4,355 IDR -3%
Nongshim Co 004370 348,500 KRW 530,619 KRW +52%

Compare Microbio Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Consumer Defensive stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Microbio Co (4128) overvalued or undervalued?
As of Jul 21, 2026, our model estimates a fair value of 24.57 TWD versus a price of 14.50 TWD, about +69% (undervalued).
What is the fair value of 4128?
Our model-based fair value for Microbio Co is 24.57 TWD (as of Jul 21, 2026), built from audited fundamentals. The current price is 14.50 TWD.
What is the quality score of 4128?
Microbio Co has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Microbio Co (4128)?
Microbio Co reported trailing-twelve-month revenue of about 1.9B TWD (latest available figure, as of Jul 21, 2026).
What is the net profit margin of 4128?
The net profit margin of Microbio Co is about -35.7%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Microbio Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.